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Introduction: Recently, analysis of DNA methylation of the
SHOX2 locus was shown to reliably identify lung cancer in bron-
chial aspirates of patients with disease. As a plasma-based assay
would expand the possible applications of the SHOX2 biomarker,
this study aimed to develop a modified SHOX2 assay for use in a
blood-based test and to analyze the performance of this optimized
SHOX2 methylation assay in plasma.
Methods: Quantitative real-time polymerase chain reaction was
used to analyze DNA methylation of SHOX2 in plasma samples
from 411 individuals. A training study (20 stage IV patients with
lung cancer and 20 controls) was performed to show the feasibility
of detecting the SHOX2 biomarker in blood and to determine a
methylation cutoff for patient classification. The resulting cutoff was
verified in a testing study composed of 371 plasma samples from
patients with lung cancer and controls.
Results: DNA methylation of SHOX2 could be used as a biomarker to
distinguish between malignant lung disease and controls at a sensitivity
of 60% (95% confidence interval: 53–67%) and a specificity of 90%
(95% confidence interval: 84–94%). Cancer in patients with stages II
(72%), III (55%), and IV (83%) was detected at a higher sensitivity
when compared with stage I patients. Small cell lung cancer (80%) and
squamous cell carcinoma (63%) were detected at the highest sensitivity
when compared with adenocarcinomas.
Conclusions: SHOX2 DNAmethylation is a biomarker for detecting
the presence of malignant lung disease in blood plasma from
patients with lung cancer.
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A total of 1,529,560 new cancer cases and 569,490 deathsdue to cancer were projected to occur in the United States
in 2010.1 Lung cancer is the second most common cancer in
both men and women representing approximately 15% of all
cancer diagnoses.1 Lung cancer surpassed breast cancer as the
leading cause of cancer death in women in 1987 and is
expected to account for 26% of all female cancer deaths in
2010.1 Among men, 29% of cancer deaths are related to lung
cancer.1 With a 5-year survival of 16%, lung cancer repre-
sents the third most lethal cancer after liver (14%) and
pancreatic cancer (6%).1
Most patients seek medical attention because of the
appearance of symptoms when the disease is at an advanced
stage and prognosis is poor. However, outcomes are signifi-
cantly better in patients diagnosed at earlier stages with a
5-year survival rate for stage I cancer ranging from 60 to
80%.2–5 Thus, it seems reasonable to attempt to detect the
disease earlier in asymptomatic patients when curative resec-
tions are a realistic option.
Computed tomography (CT) as a screening tool for
early lung cancer detection is currently being evaluated in
large ongoing trials.6,7 The huge randomized National Lung
Screening Trial (NLST) in the United States has just been
stopped after 8-year results showed that screening heavy
smokers with low-dose helical CT significantly reduced
deaths from lung cancer, compared with screening with chest
x-rays.8 This study showed that screening decreases mortal-
ity, and as a result CT might turn into an accepted method for
lung cancer screening.
Molecular biomarkers might have potential for im-
proving the management of lung cancer in clinical rou-
tine8,9 and might allow for the early detection of the
disease. As CT screening is a sensitive but less specific
procedure causing significant downstream diagnostic
costs, an additional, more specific parameter would be of
tremendous use in the evaluation of the CT result and for
further treatment decisions.
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DNA methylation plays a key role in fundamental
biological processes,10 and aberrant DNA methylation of
certain loci has been reported to play a major role in carci-
nogenesis.11 Such epigenetic modifications are highly infor-
mative and robust and are therefore a promising source for
cancer biomarkers for improving diagnosis and treatment of
cancer.12 Recently, real-time polymerase chain reaction
(PCR) analysis of SHOX2 DNAmethylation was described as
a valuable biomarker for detecting lung cancer in bronchial
aspirates obtained during bronchoscopy.13 In a case-control
study with more than 500 patients, lung cancer could be
detected with sensitivity of 68% and at high specificity of
95%. In addition, SHOX2 DNA methylation allowed for
accurate detection of lung cancer even in patients having no
visible tumor in bronchoscopy and a negative cytology. A test
for SHOX2 methylation has recently become commercially
available in Europe as an in vitro diagnostic test to aid
pathologists in the diagnosis of lung cancer. The test that
analyzes methylated SHOX2 DNA, derived from tumor cells
present in bronchial aspirates, is highly specific and sensitive.
However, the test is limited to patients undergoing bronchos-
copy and hence is not suitable for screening asymptomatic
patients or for combining molecular biomarkers with noninva-
sive diagnostic procedures (e.g., CT scanning). For such ap-
proaches, tests based on standard specimens, such as serum or
plasma, are required. During cancer development and progres-
sion, tumor cells release DNA into the bloodstream. Such
circulating DNA can be analyzed in serum or plasma for DNA
biomarkers, including DNA methylation biomarkers.14–18
In the present study, the real-time PCR-based assay for
analysis of SHOX2 methylation was tested in blood plasma
from 411 individuals to distinguish between malignant lung
disease and controls (healthy individuals, benign lung dis-
ease, and patients with prostate cancer). A training study (20
patients with stage IV lung cancer and 20 controls) was first
performed to show the feasibility of detecting the SHOX2
biomarker in blood and to determine a methylation cutoff for
patient classification. The resulting cutoff was then verified in
a testing study composed of 371 plasma samples.
MATERIALS AND METHODS
Patients
Plasma samples were collected at three independent sites
with appropriate written consent under approval of the local
ethics committees. Sixty-one specimens (testing study) were
provided by the Charite´ University Hospital (Berlin, Germany),
289 (testing study) and 40 specimens (training study) were
obtained from Oncomatrix, Inc., (San Marcos, CA), and 21
samples (testing study) were from Rainier Clinical Research
Center, Inc. (Renton, WA). Samples from 343 patients (testing
study) passed the sample quality control acceptance criterion as
described in the section “Data and Statistical Analysis” and were
suited for analyzing the SHOX2 DNA methylation. The char-
acteristic of this population (testing study only) is described
in more detail in Table 1. Gender and age data were not
available for many patients (Table 1). Therefore, the analyzed
cases and controls were neither sex- nor age-matched. How-
ever, a previous study based on the analysis of bronchial
aspirates showed that age and sex had no impact on the
SHOX2 DNA methylation level.13
Sample and Calibrator Preparation
DNA extraction from plasma samples, bisulfite con-
version, and purification were performed using the Epi
proColon Plasma DNA Preparation Kit (Epigenomics AG,
Berlin, Germany).
A calibrator sample with a defined methylation level
was prepared by mixing bisulfite-converted DNA from sperm
cells with bisulfite-converted methylated DNA (Millipore,
Billerica, MA). DNA extraction from sperm cells and the
bisulfite conversion of sperm DNA and methylated DNA
were carried out as described previously.19 The DNA con-
centration of sperm and universal methylated DNA was
determined by ultraviolet spectrophotometry using a Nano-
drop ND-1000 spectral photometer (Nanodrop Technologies,
Wilmington, DE).
Real-Time PCR
Real-time PCR assays were duplexed in one reaction:
an assay for quantification of total input DNA and a methy-
TABLE 1. Characteristics of the Patient Population (Testing
Set Only)
Total Cases Controls
Age, n (%) 343 (100) 188 (100) 155 (100)
50 yr, n (%) 39 (11) 16 (10) 23 (15)
51–60 yr, n (%) 76 (22) 45 (24) 31 (20)
60 yr, n (%) 66 (19) 36 (19) 30 (19)
Unknown, n (%) 162 (47) 91 (48) 71 (46)
Median 57 58 56
Range 45–78 45–78 45–77
Gender, n (%)
Male 200 (58) 122 (65) 78 (50)
Female 68 (20) 29 (15) 39 (25)
Unknown 75 (22) 37 (20) 38 (25)
Histology subtype, n (%)
Squamous cell
carcinoma
38 (20) —
Adenocarcinoma 31 (16) —
SCLC 15 (8) —
Other/unknown lung
cancer histology
104 (55) —
Benign lung disease
and healthy
— 151 (97)
Other cancer (prostate
cancer)a
— 4 (3)
Stage (UICC), n (%)
I — 37 (20) —
II — 29 (15) —
III — 53 (28) —
IV — 42 (22) —
Unknown — 27 (14) —
Clinical data of the 343 analyzed patient samples (188 55% cases and 155 45%
controls). Twenty-eight samples failed the sample quality control because their DNA
yield was too low. They were excluded from analysis and are not included in this table.
a The prostate cancer patients were classified as controls in the determination of
specificity of the SHOX2 biomarker for lung cancer.
SCLC, small cell lung cancer; UICC, Union for International Cancer Control.
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lation-specific HeavyMethyl (HM) assay for quantification of
methylated SHOX2. The assay for total input DNA quantifi-
cation was composed of two methylation-unspecific oligonu-
cleotides and a Taqman probe for amplifying a region within
the ACTB gene locus. The quantitative methylation-specific
SHOX2 assay (HM assay) is composed of two methylation-
unspecific primers, two methylation-specific blockers (one
blocking each primer), and a Taqman probe, which specifi-
cally amplified methylated DNA within the SHOX2 gene
locus. PCR was performed in a total volume of 40 l
containing 20 l Epi proLung BL Master Mix (Epigenomics
AG), 15 l DNA eluate from plasma extraction, and 5 l
water. Real-time PCR was performed using a 7500 Fast
real-time PCR instrument (Applied Biosystems, CA) with the
following temperature profile: 20 min/95°C, 55 cycles with
15 sec/95°C, and 30 sec/56°C.
Data and Statistical Analysis
For each sample, a relative methylation value was
determined using the CT method.20 In contrast to Schmidt
et al.,13 the calculation was modified as follows: CTSample 
CTSample  CTCalibrator, where CTSample  CTSample/
Methylation Quantification Assay  CTSample/Total Quantification Assay
and CT Calibrator  CTCalibrator/Methylation Quantification Assay 
CTCalibrator/Total Quantification Assay. CTs were measured in tripli-
cate. Percentage methylation was calculated using the following
formula: MethylationSample  MethylationCalibrator  2
CT.
Samples were excluded from the study when more than
two replicates of the total DNA quantification assay showed
cycle threshold values more than 35.
A methylation cutoff was assigned based on the results of
the training study for dichotomization of the methylation value.
The performance of the assay was reported by means of
sensitivity and specificity. Sensitivity was defined as the ratio
of correctly assigned positive lung cancer samples in all lung
cancer samples. Specificity was defined as the ratio of cor-
rectly assigned negative samples in all normal/benign lung
and other cancer (prostate cancer) samples. The prostate
cancer samples were classified as controls in the determina-
tion of specificity of the SHOX2 biomarker for lung cancer.
The impact of tumor stage and histology on SHOX2
DNA methylation was tested by logistic regression for
grouped data. The area under the curve of the receiver
operating characteristic (ROC) was computed using the trap-
ezoidal rule. ROC analyses and logistic regression were
carried out using IBM SPSS Statistics (IBM, Armonk, NY).
RESULTS
The real-time PCR duplex assay originally developed
for sensitive quantification of methylated SHOX2 DNA in a
background of high amounts of unmethylated DNA in bron-
chial aspirates13 was modified to meet the conditions for
plasma analysis. The modified assay was based on replace-
ment of the Scorpion probe with Taqman technology and
optimized buffer conditions. The analytical performance of
the assay is shown in Figure 1. Different amounts (0–720 pg)
of bisulfite-converted, artificially methylated DNA were
spiked into a background of 50,000 pg unmethylated DNA
from sperm to characterize the performance of the assay. The
assay allowed for the reliable detection (12 of 12 replicates)
of 15 pg (5 haploid human genome equivalents) of meth-
ylated DNA in a background of 50,000 pg unmethylated
DNA, respectively (1:3400). Lower amounts of methylated
DNA, down to one haploid genome equivalent (3 pg), were
sporadically detected, which is to be expected when analyz-
ing single copies of DNA.
For clinical performance evaluation of the assay in
plasma, DNA methylation was quantified by real-time PCR
in two case-control studies comprising a total of 411 plasma
samples (222 cases and 189 controls). A small case-control
study including plasma samples from 20 patients with stage
IV lung cancer (cases) and from 20 healthy individuals and
patients with benign lung disease (controls) was conducted to
show that SHOX2 DNA methylation is a useful lung cancer
FIGURE 1. Analytical assay performance. Analytical perfor-
mance of the quantitative real-time polymerase chain reac-
tion assay for quantifying SHOX2 DNA methylation. Different
amounts of methylated DNA (3–720 pg) were spiked into a
background of 50,000 pg unmethylated DNA. Number of
replicates: 12 (0–60 pg), 6 (180 and 360 pg), and 4 (720
pg), respectively.
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FIGURE 2. Results of the training study. Plasma from 20
individuals without cancer (controls) and 20 late stage
(stage IV) patients with lung cancer (cases) was analyzed.
Shown is a receiver operating characteristic plot (A) and the
single SHOX2 methylation values (B). A methylation cutoff of
0.05% was used to discriminate between plasma from cases
and controls (B).
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biomarker in blood plasma. The results of this training study
are shown in Figure 2. Higher SHOX2 DNA methylation can
be found in plasma samples from cases in comparison with
the controls (Figure 2). As described for bronchial aspirates
samples,13 background DNA methylation of the SHOX2 gene
was found in most samples, thus necessitating the implemen-
tation of a clinical cutoff to dichotomize the quantitative
methylation value into a qualitative result (test negative or
test positive). Based on the results, the cutoff was chosen to
reduce the false-positive rate to 5% for controls, resulting in
a cutoff of 0.05%. According to this clinical cutoff, samples
with methylation values more than 0.05% were rated as test
positive, whereas samples with methylation values less than
0.05% were rated as test negative. Using this cutoff, 15 of 20
patients with lung cancer were classified as SHOX2 methyl-
ation positive resulting in a sensitivity of 75%. Nineteen of 20
control samples were classified as SHOX2 methylation neg-
ative leading to a specificity of 95% (Figure 2).
The cutoff (0.05%) was further verified and the clinical
performance evaluated in a testing study composed of 371
plasma samples from patients with lung cancer (cases),
healthy individuals, benign lung diseases, and patients with
prostate cancer (controls). In this study, 28 samples (7.5%; 14
cases and 14 controls) failed quality control specification and
were excluded from analysis because the DNA yield was
insufficient as indicated by high cycle threshold values of the
total quantification assay. The results from the remaining 343
samples are listed in Table 2 and Figure 3.
Out of 188 valid lung cancer patient samples, 112
samples (60%; 95% confidence interval [CI]: 53–67%)
showed CT values above the cutoff value of 0.05% and
were therefore classified as test positive. Out of 155 valid
controls, 139 samples (90%; 95% CI: 84–94%) showed
CT values below the cutoff of 0.05% and were therefore
classified as test negative (Table 2). All of the prostate cancer
patient samples were test negative. Five other controls
showed high plasma levels of SHOX2 DNA methylation
more than 1% (Figure 3). Follow-up data for these patients
were not available. Therefore, it could not be excluded that
these patients developed cancer after blood collection. Sen-
sitivity and specificity of the assay for all possible cutoffs are
shown in Figure 4A. ROC analysis resulted in an area under
the curve of 0.78 (95% CI: 0.74–0.84). Figure 4B shows the
sensitivity and specificity in relation to alternative methyl-
ation values as cutoffs. The specificity only slightly increases,
whereas the sensitivity decreases when using lower methyl-
ation values as cutoffs. The clinical performance with regard
to the pathologically determined cancer stage (I–IV, Union
for International Cancer Control [UICC]) is listed in Table 2.
Patients with stages II (72%), III (55%), and IV (83%) were
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FIGURE 3. Results of the testing study. Box plot
displaying SHOX2 DNA methylation values mea-
sured in controls, cases, and in cases according to
tumor stages. A methylation cutoff of 0.05% as
determined in the training study was used to
stratify patients into SHOX2 methylation-positive
(0.05%) and SHOX2 methylation-negative
(	0.05%) groups.
TABLE 2. Clinical Performance
Tumor Stages
Histology
Adenocarcinoma Squamous Cell Carcinoma SCLC Unknown/Other All
I 2/10 (20%) 6/14 (43%) 1/3 (33%) 1/10 (10%) 10/37 (27%)
II 4/9 (44%) 7/8 (88%) 2/2 (100%) 8/10 (80%) 21/29 (72%)
III 0/1 (0%) 8/9 (89%) 4/5 (80%) 17/38 (45%) 29/53 (55%)
IV 2/3 (67%) 0/0 1/1 (100%) 32/38 (84%) 35/42 (83%)
Unknown 4/8 (50%) 3/7 (42%) 4/4 (100%) 6/8 (75%) 17/27 (63%)
All 12/31 (39%) 24/38 (63%) 12/15 (80%) 64/104 (62%) 112/188 (60%)
Stage and histology-specific performance of the SHOX2 DNAmethylation biomarker using plasma samples from patients with suspected lung cancer. In total, 371 plasma samples
(169 controls and 202 cases) were analyzed. Valid results were obtained from 343 (92%) samples (155 controls and 188 cases). One hundred twelve cases were SHOX2 positive,
resulting in an overall sensitivity of 60%. Sixteen controls were SHOX2 methylation positive, resulting in a specificity of 90%.
SCLC, small cell lung cancer.
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detected with higher sensitivity when compared with stage I
patients (27%). Overall, small cell lung cancer (SCLC; 80%)
and squamous cell carcinoma (63%) were detected at the
highest sensitivity when compared with adenocarcinomas
(39%). The association between clinicopathological features
(stage and histology) and SHOX2 DNA methylation status
(positive and negative) was analyzed in more detail using
univariate logistic regression. Histology (p  0.032) and
stage (p 	 0.0001) were determined to have significant
correlation with SHOX2 DNA methylation.
Both the stage-dependent and histology-dependent dis-
tribution of sensitivity in bronchial aspirates are strongly
concordant with the findings of Schmidt et al.13
DISCUSSION
DNA methylation has been shown to play an important
role in carcinogenesis at an early stage.11 That makes DNA
methylation alterations among the most promising candidates
in biomarker research. Several previous studies specifically
targeted DNA methylation biomarkers for their potential to
improve clinical lung cancer management.19,21–25 Recently,
DNA methylation of the SHOX2 gene was shown to be a
useful tumor marker for aiding in the diagnostic workup for
suspected lung cancer.13 Bronchial aspirates are used as the
sample material for this assay, and the test is therefore
restricted to patients with suspected lung cancer undergoing
bronchoscopy. However, bronchoscopy is not considered for
screening purposes on asymptomatic individuals. Successful
detection of the DNA methylation biomarker SHOX2 in
blood might enable its use for screening purposes.
In this study, DNA methylation of SHOX2 was found to
be a sensitive (60%; 95% CI: 53–67%) and specific (90%;
95% CI: 84–94%) biomarker for identifying patients with
lung cancer based on the analysis of blood plasma. Sensitivity
and specificity are slightly lower when using plasma when
compared with bronchial aspirates.13 Compared with bron-
chial aspirates obtained directly at the region of interest,
plasma samples are more challenging, as the total amount of
lung-derived DNA and the fraction of tumor DNA are ex-
pected to be significantly lower. In addition, blood plasma
contains a complex mixture of DNA originating potentially
from any part of the body, i.e., the analytical performance
requirements for analyzing these body fluids are higher and
the markers need to be specific for lung tumor DNA to ensure
a high specificity of the test. Recently, the methylation
biomarker SEPT9 was described15 as a highly sensitive and
specific DNA methylation biomarker for colorectal cancer
based on the analysis of plasma. For the present study, the
same protocols and components for DNA extraction, DNA
bisulfite conversion, and purification were used. In addition,
the SHOX2 assay for real-time PCR was optimized for
detection of plasma-derived DNA in comparison with the
previous study on bronchial aspirates.13 The new assay uses
the same oligonucleotides for priming and blocking but
changes the detection technology from Scorpion to TaqMan
probes in an optimized buffer system to achieve maximum
sensitivity and specificity. However, the method used for the
preparation of bisulfite DNA from plasma was originally
developed for usage in conjunction with the biomarker
SEPT9. The presence of methylated SEPT9 is associated with
the detection of invasive colorectal adenocarcinoma.15 In
contrast, this study showed that SHOX2 DNA methylation is
not a qualitative but a quantitative biomarker, which might
require an adapted protocol for DNA preparation. Therefore,
an optimized method, i.e., gentle bisulfite chemistry26 and
optimized purification protocols to avoid PCR inhibition,
might improve sensitivity and specificity of the SHOX2
biomarker. SHOX2 is located on chromosome 3q, a region
that has been recognized as one of the most prevalent and
significant for chromosomal rearrangements, i.e., genomic
gain, in lung cancer.27–29 In a recent publication, amplifica-
tion of the SHOX2 gene locus was frequently observed in
lung cancer samples, and amplification correlated with hy-
permethylation of the SHOX2 gene.26 The high performance
of SHOX2 DNA methylation as a biomarker, even in chal-
lenging samples such as plasma, might be due to combined
effects of locus amplification and DNA methylation of
SHOX2 in tumor cells. As a result, an increase in methylated
SHOX2 DNA copies in tumor cells compared with normal
cells also increases the SHOX2 DNA methylation level in
plasma, thereby facilitating sensitive detection.
The methylation level of samples from patients with
stage I disease was found to be significantly lower than from
patients with more advanced malignant disease. This was also
observed when bronchial aspirates were used as the sample
type.13 The most likely explanation is the smaller size of the
tumor resulting in a decreased amount of tumor-specific DNA
being released into the bloodstream. Because of the lower
A B
SHOX2
FIGURE 4. Results of the clinical
performance evaluation study. A, Re-
ceiver operating characteristic plot. B,
Resulting sensitivity and specificity of
the assay when using alternative cut-
offs for patient stratification.
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sensitivity of the SHOX2 biomarker for stage I tumors,
additional biomarkers may be required for early detection of
the disease. However, SHOX2 DNAmethylation alone allows
for the detection of stage II tumors with high sensitivity
(72%) and it would represent an improvement of the current
standard of care. For bronchial aspirate samples, the investi-
gation of the impact of histological lung cancer subtypes on
the methylation levels of bronchial aspirates showed that
patients with SCLC and squamous cell carcinoma have
higher levels of methylation than patients with adenocarci-
noma.13 This differential detection was confirmed by the
present study, suggesting that a second biomarker specific for
adenocarcinoma might further increase the sensitivity of a
blood-based test.
The assay used in this study for determining the
DNA methylation of SHOX2 in blood is a quantitative
assay providing information on the relative abundance of
the tumor marker in the blood. This information might be
further exploited, for instance, for monitoring SHOX2
methylation-positive patients after surgery to detect a re-
currence of the disease.
CT as a screening tool for early lung cancer detection is
currently being evaluated in large ongoing trials. Recent
results from the NLST provided clear evidence that lung
cancer screening decreases mortality in the screened popula-
tion, and therefore, CT is likely to play an important role in
the future management of lung cancer. CT has already been
shown to allow for the detection of early lesions, in particular,
peripheral adenocarcinomas.7 A biomarker in combination
with CT might further improve lung cancer screening results
and should be evaluated in more detail. CT scans perform
well for detecting small peripheral lesions, especially adeno-
carcinoma. However, CT scans fail to detect preinvasive
lesions and early lung cancer in the central airways, specifi-
cally SCLC and early stages of squamous cell carcinoma,
which comprise 17 to 29% of all lung cancers.30 McWilliams
et al.31 found 28 lung cancer cases in a screened group of 561
high-risk patients (5%). Seven (25%) of the detected malig-
nant cases were found by bronchoscopy but not by image
evaluation. The addition of biomarkers in conjunction with a
CT might help to identify these patients using diagnostic tools
less invasive than bronchoscopy.
Recent advancements in CT technology allowed for the
detection of smaller lung nodules leading to a high sensitivity
of this method. In the NELSON trial for instance, round 1
screening showed 94.6% (95% CI: 86.5–98%) sensitivity
resulting in negative predictive value of 99.9% (95% CI:
99.9–100%).32 Therefore, the performance requirements for
a biomarker, which could further contribute clinically valu-
able information to a group of people with negative CT scans,
are considerably high. On the other hand, the group with
clearly positive CT results (i.e., nodules 500 mm3 [Ø 9.8
mm] or doubling time 	400 days), which represented 2.6%
and 1.8% of the participants32 in the first and second round of
the NELSON trial, respectively, is relatively small. However,
for this group, further reliable diagnostic procedures, i.e.,
bronchoscopy, are highly recommended due to the high
prevalence of lung cancer in this group. The DNA methyl-
ation biomarker SHOX2 was already shown to be a clinically
valuable biomarker in a group of patients undergoing first-
time bronchoscopy for suspected lung cancer because it
allowed for the confirmation of the presence of a malignant
disease based on bronchial aspirates, which were obtained
during bronchoscopy.13 The screening trials also showed that
a large number of nodules were seen by CT, resulting in
many indeterminate scans. Nodules with volumes between 50
and 500 mm3 and doubling times between 400 and 600 days
were considered indeterminate32 in the NELSON trial, which
reflected 19.2% of the screened population32 during first
round scanning. Patients with these results still have an
elevated risk of having lung cancer when compared with the
whole screen population but CT screening is of limited value
for them. Furthermore, invasive diagnostic procedures could
lead to increased morbidity and mortality and a presumed
increase in participant’s anxiety. A biomarker, such as
SHOX2 DNA methylation, which may allow for a highly
specific detection of lung cancer in this group with indeter-
minate nodules, could potentially be of high clinical value in
this group of patients.
The NLST was completed in 2010, and the Director of
the National Cancer Institute reported that the randomized
trial of low-dose CT screening, when compared with screen-
ing by chest x-ray, resulted in a 20% reduction in lung
cancer-related mortality.8 The publication of the NLST re-
sults is expected in 2011. However, at this time routine
screening for lung cancer using imaging is not yet recom-
mended by any major medical organization.7,33 A defined
strategy, possibly including biomarkers such as DNA meth-
ylation of SHOX2, to assist in the management of indetermi-
nate lung nodules would be an appropriate consideration
before the implementation of CT as a standard method for
lung cancer screening.
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